Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/062872external-prioritypatent/WO2012016889A2/en
Application filed by Chiesi Farma SpafiledCriticalChiesi Farma Spa
Publication of TN2013000015A1publicationCriticalpatent/TN2013000015A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The invention relates to a pharmaceutical formulation in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient. The invention also relates to the process for the preparation thereof, and to its use in the prevention and/or treatment of a respiratory disease such as asthma and COPD
TNP2013000015A2011-07-272013-01-22Dry powder formulation comprising a phosphodiesterase inhibitor
TN2013000015A1
(en)
Compounds and compositions as c-kit kinase inhibitors, pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating diseases
Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of alzheimer's disease